Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. - Wikidata - awgldk - TriplyDB

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.

http://www.wikidata.org/entity/Q36341628

about

Beyond BRAF: where next for melanoma therapy?Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date Targeting lung cancer through inhibition of checkpoint kinases.A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.Targeting cell cycle regulators in hematologic malignancies.Rational Combinations of Targeted Agents in AML Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.Cell cycle proteins as promising targets in cancer therapy Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.Emerging cell cycle inhibitors for acute myeloid leukemia.WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia.Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer.Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer.Directing the use of DDR kinase inhibitors in cancer treatment.Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers.Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.

P2860

Q27006853-A97EFB45-C6B4-43F9-9ECD-FAEFE82FCFD2 Q28086993-9DD46398-845B-4BA2-84AE-EAF6DBB7F187 Q33887664-4BFD894F-E930-4AC7-9115-4B7F10DBB340 Q35128547-81F5DAF7-5556-4901-AC67-8C9279FE3B3F Q35287823-5FB81DBB-CC5B-4AEC-8F01-9A8E9CF67E42 Q35334436-61664725-3C8B-4F15-AF7E-6C623D4AFF0C Q35750491-972E4334-5085-489F-AF2E-A001A67C3D58 Q36162494-2997686F-D718-4D38-BB44-5C9AA475F3EA Q36413964-6FD49091-81C5-4B09-8735-E110DD6C0972 Q36545758-D9BDE75C-C24E-457D-9CA9-0A51842023E3 Q37693690-785DC928-EA34-49FB-AE24-80ECBC4B69D0 Q38261022-AD656350-DEC0-4CF6-8782-27A275E43F60 Q38429500-5E690B7D-6CDA-4CC5-9037-019044FA9FB6 Q38782798-5454BFF8-3EE9-40F7-84B5-BA212C3054B1 Q38785380-EC4C9C03-E5CD-489F-930F-0B2412B7037F Q38904522-A24B123E-D5DA-4FFB-B7AC-A7015948ABE6 Q42231927-3D29F5E8-8DB3-46A6-A08F-261F7A7BF942 Q42366556-5740347B-4518-49FA-9A25-7A5B4CEC4BB9 Q47687840-0CD71C8A-0EE5-4E2F-978F-04A8444F6071 Q48689511-F5BCD6BF-CA94-47DB-9FAA-DBB5398CDDCD Q50896526-FD662210-C209-4517-9E6D-72AD1E5062CE

P2860

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.

http://www.wikidata.org/entity/Q36341628

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Identification of Wee1 as a no ...... ukemia and other malignancies.

@ast

Identification of Wee1 as a no ...... ukemia and other malignancies.

@en

type

label

Identification of Wee1 as a no ...... ukemia and other malignancies.

@ast

Identification of Wee1 as a no ...... ukemia and other malignancies.

@en

prefLabel

Identification of Wee1 as a no ...... ukemia and other malignancies.

@ast

Identification of Wee1 as a no ...... ukemia and other malignancies.

@en

P1433

Q36341628-B51B8998-B46B-4C4F-8E15-59045E5EC0A9

P1476

Q36341628-34D40DF2-C780-4774-AF3C-615E8FB00A47

P2093

Q36341628-068E8B68-E6BC-4FE4-86E8-10850FBF2346

Q36341628-2CAB885E-4EC9-44FB-A48B-53B3553102DC

Q36341628-2FA9D015-A6D2-4EA4-9F61-A94E1B4CD32D

Q36341628-361855B2-CF39-4AEF-A9AF-8589F1B76488

Q36341628-4EC388B3-CAD4-427A-85C8-E9B234C0DF4A

Q36341628-5445C4AD-E05D-42B2-83BD-E37D9A48E208

Q36341628-61A828E2-0AA3-49CA-9E1C-0E8FE801F3B9

Q36341628-63C2BB30-C692-49FD-B418-A7EBDBA077DE

Q36341628-63E8AA0F-883E-41FC-8982-FC2220408CAE

Q36341628-6510CD38-F347-4557-91AA-33DFED641EE5

P2860

Q36341628-010B2647-2E3C-4156-8DC8-82EC7AD08178

Q36341628-04916734-4CD4-4C33-91C4-1C9A30F190CE

Q36341628-0679F70C-D90B-40B8-94D6-6C3DC6CDEDB0

Q36341628-12ABB766-0533-4F39-BE76-F3BE4968BA45

Q36341628-1819672C-A4F4-42D1-8011-044203911574

Q36341628-1AE6CCE4-62A6-4BCC-8124-D697DD788870

Q36341628-2118A0AF-A0C3-41B6-83D2-64992C850974

Q36341628-22189592-6A01-4552-9D48-A83250C29484

Q36341628-24296A91-3925-4804-986D-ACD02A75937F

Q36341628-28AEFE89-FB01-4BB2-81A0-0F023D56F225

P2888

Q36341628-86C4BCCF-E4A8-47A9-9FF8-D02D4B2F8B17

P304

Q36341628-DC92BCDA-AAE1-4E71-8859-B3B9B4DEE4BA

P31

Q36341628-5D4306B7-8303-4C1A-8EB4-F22B5C640E07

P356

Q36341628-EA1D9F14-3019-4BD5-AE05-EE3B6EFCC36E

P433

Q36341628-7AC127A2-F6AD-4F19-9392-769C4BEB75EF

P478

Q36341628-DF888D90-E329-4A45-ADC6-493B6872E8A2

P577

Q36341628-0900BA6A-F33D-42E2-9344-53029EE2A66C

P698

Q36341628-442C01A4-F370-4B00-8F10-09652B173654

P921

Q36341628-A0C8BCF0-A6A9-488E-B260-455B77EA882B

P932

Q36341628-332DD7B7-A618-47BF-ABE7-59D36D925E35

P356

P1433

P1476

Identification of Wee1 as a no ...... ukemia and other malignancies.

@en

P2093

Amanda L Christie

http://www.w3.org/2001/XMLSchema#string

Atsushi Nonami

http://www.w3.org/2001/XMLSchema#string

Constantine Mitsiades

http://www.w3.org/2001/XMLSchema#string

Ellen Weisberg

http://www.w3.org/2001/XMLSchema#string

Erik Nelson

http://www.w3.org/2001/XMLSchema#string

Feiyang Liu

http://www.w3.org/2001/XMLSchema#string

James D Griffin

http://www.w3.org/2001/XMLSchema#string

Jianming Zhang

http://www.w3.org/2001/XMLSchema#string

Kristen Cowens

http://www.w3.org/2001/XMLSchema#string

Kwok-Kin Wong

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15

Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

Implications of NRAS mutations in AML: a study of 2502 patients.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Targeting RAS signalling pathways in cancer therapy

Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

P2888

P304

27-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2014.149

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24791855

http://www.w3.org/2001/XMLSchema#string

P921

P932

4667710

http://www.w3.org/2001/XMLSchema#string